Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

NCT02725957
View directory record Official record
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 16, 2026, 9:54 PM EDT
Withdrawn Phase 2 Interventional

Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations

NCT00624312
View directory record Official record
Conditions
Cancer
Interventions
Procrit, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

NCT01900431
View directory record Official record
Conditions
Uveitis
Interventions
Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 16, 2026, 9:54 PM EDT
Not yet recruiting Early Phase 1 Interventional

Mechanistic Clinical Trial of PCSK9 Inhibition for AAA

NCT06081153
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

NCT02116972
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006 32 mg, Placebo, FX006 16 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
39
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 16, 2026, 9:54 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Abatacept for SLE Arthritis (IM101-330)

NCT02429934
View directory record Official record
Conditions
Systemic Lupus Erythematosus Arthritis
Interventions
abatacept also known as Orencia also known as CTLA4-Ig, Placebo
Biological · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 16, 2026, 9:54 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 9:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal

NCT00851747
View directory record Official record
Conditions
Obesity
Interventions
Phosphatidylcholine Deoxycholate, Saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
25 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

Clonidine Versus Adenosine to Treat Neuropathic Pain

NCT00349921
View directory record Official record
Conditions
Pain
Interventions
clonidine, adenosine, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT Study

NCT05727384
View directory record Official record
Conditions
Inflammation, Frailty
Interventions
Clazakizumab, Placebo
Drug
Lead sponsor
Anne B. Newman
Other
Eligibility
70 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 9:54 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Does a ThoracoLumbar Interfacial Plane (TLIP) Block With Liposomal Bupivacaine Provide TLIP Block in Spinal Surgery

NCT04865211
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Liposomal bupivacaine, Bupivacaine Injection, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 16, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Raptiva
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 16, 2026, 9:54 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

NCT00436748
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Kidney Disease
Interventions
Darbepoetin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 16, 2026, 9:54 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

NCT07428538
View directory record Official record
Conditions
Hepatitis
Interventions
Larsucosterol, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 9:54 PM EDT
Terminated Phase 1 Interventional

Effects of IGF-I in HIV Metabolic Disease

NCT01329744
View directory record Official record
Conditions
HIV Lipodystrophy
Interventions
mecasermin, Placebo control
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 16, 2026, 9:54 PM EDT
Recruiting Phase 2 Interventional

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

NCT07580716
View directory record Official record
Conditions
Primary Knee Osteoarthritis
Interventions
Allocetra, Placebo
Drug · Other
Lead sponsor
Enlivex Therapeutics Ltd.
Industry
Eligibility
64 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Longwood, Florida • Miami, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

NCT04053634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
84
States / cities
Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

NCT00624338
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 16, 2026, 9:54 PM EDT
Terminated Phase 2 Interventional Results available

Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets

NCT04899921
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
Ipilimumab, Nivolumab, Troriluzole, Placebo
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 16, 2026, 9:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of MGD010 in Healthy Subjects

NCT02376036
View directory record Official record
Conditions
Healthy Subjects
Interventions
MGD010, Placebo, Hepatitis A vaccine
Drug · Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 50 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 16, 2026, 9:54 PM EDT
Recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
169
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 16, 2026, 9:54 PM EDT